12/4
07:00 am
ppbt
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Medium
Report
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
11/29
12:31 am
ppbt
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at
Wall Street Z
Medium
Report
Purple Biotech (NASDAQ:PPBT) was downgraded by analysts at
Wall Street Z
10/29
07:33 am
ppbt
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
High
Report
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
10/20
04:00 pm
ppbt
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Low
Report
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
9/10
08:32 am
ppbt
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance [Yahoo! Finance]
Medium
Report
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance [Yahoo! Finance]
9/10
08:00 am
ppbt
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
High
Report
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
9/5
04:00 pm
ppbt
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Medium
Report
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants